Strides Shasun receives USFDA approval for Ranitidine tablets
24 August 2016 | News | By BioSpectrum Bureau
Strides Shasun receives USFDA approval for Ranitidine tablets
Strides Shasun Limited today announced that it has received approval from the United States Food & Drug Administration (USFDA) for Ranitidine Tablets USP, 150 mg and 300 mg.
Ranitidine tablet is the first integrated product approval where the API and formulations will be manufactured at erstwhile Shasun Pharmaceutical's Cuddalore and Pondicherry facilities respectively.
According to IMS data (MAT June 2016), the US market for Ranitidine Tablets USP, 150 mg and 300 mg. is approximately USD 125 Million.
The product to be launched immediately will be marketed by Strides Pharma Inc in the US Market.
Also read: Vyome Biosciences closes $14 million series C financing
